FI991187A - Immunoterapeuttisia imidejä/amideja PDE IV ja TNF inhibiittoreina - Google Patents
Immunoterapeuttisia imidejä/amideja PDE IV ja TNF inhibiittoreina Download PDFInfo
- Publication number
- FI991187A FI991187A FI991187A FI991187A FI991187A FI 991187 A FI991187 A FI 991187A FI 991187 A FI991187 A FI 991187A FI 991187 A FI991187 A FI 991187A FI 991187 A FI991187 A FI 991187A
- Authority
- FI
- Finland
- Prior art keywords
- pde
- amides
- tnf inhibitors
- immunotherapeutic
- imides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/759,788 US5703098A (en) | 1994-12-30 | 1996-12-03 | Immunotherapeutic imides/amides |
PCT/US1997/022369 WO1998024763A2 (en) | 1996-12-03 | 1997-12-03 | Immunotherapeutic imides/amides as pde iv and tnf inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
FI991187A0 FI991187A0 (fi) | 1999-05-25 |
FI991187A true FI991187A (fi) | 1999-07-16 |
Family
ID=25056962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI991187A FI991187A (fi) | 1996-12-03 | 1999-05-25 | Immunoterapeuttisia imidejä/amideja PDE IV ja TNF inhibiittoreina |
Country Status (13)
Country | Link |
---|---|
US (1) | US5703098A (fi) |
EP (1) | EP0942902A2 (fi) |
JP (1) | JP2001506611A (fi) |
KR (1) | KR20000069374A (fi) |
CN (1) | CN100372836C (fi) |
AU (1) | AU735540B2 (fi) |
CA (1) | CA2273002A1 (fi) |
FI (1) | FI991187A (fi) |
HU (1) | HUP0000232A3 (fi) |
NZ (1) | NZ336713A (fi) |
RU (1) | RU2177471C2 (fi) |
SK (1) | SK73299A3 (fi) |
WO (1) | WO1998024763A2 (fi) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
WO1998006692A1 (en) * | 1996-08-12 | 1998-02-19 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
WO1998052588A1 (fr) * | 1997-05-21 | 1998-11-26 | Medion Research Laboratories Inc. | Agents therapeutiques adaptes a des affections respiratoires |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
EP2193808A1 (en) | 1999-08-21 | 2010-06-09 | Nycomed GmbH | Synergistic combination |
US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US7491634B2 (en) * | 2006-04-28 | 2009-02-17 | Asm International N.V. | Methods for forming roughened surfaces and applications thereof |
US7208516B2 (en) * | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
AU2003262187A1 (en) * | 2002-04-12 | 2003-10-27 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
NZ536050A (en) * | 2002-04-12 | 2007-11-30 | Celgene Corp | Methods of identifying modulators of angiogenesis using stem cells with the proviso the stems cells are not totipotent |
NZ570777A (en) | 2002-05-17 | 2009-04-30 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
NZ539534A (en) * | 2002-10-15 | 2008-06-30 | Celgene Corp | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
AU2003290652B2 (en) | 2002-11-06 | 2008-06-19 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
KR20050072790A (ko) * | 2002-11-06 | 2005-07-12 | 셀진 코포레이션 | 골수증식 질환의 치료 및 관리를 위한 선택적 시토킨 억제약물의 사용 방법 및 이를 포함하는 조성물 |
BR0316259A (pt) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
MXPA05005161A (es) * | 2002-11-18 | 2005-07-22 | Celgene Corp | Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida. |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
EA200501548A1 (ru) * | 2003-04-01 | 2006-02-24 | Апплайд Резеч Системз Арс Холдинг Н.В. | Ингибиторы фосфодиэстераз при бесплодии |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
JP2007511618A (ja) | 2003-11-19 | 2007-05-10 | シグナル ファーマシューティカルズ,エルエルシー | インダゾール化合物およびタンパク質キナーゼ阻害剤としてのその使用方法 |
JP2007533760A (ja) * | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | 肺高血圧症を治療し管理するための、pde4モジュレーターの使用方法及びpde4モジュレーターを含む組成物 |
US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
AU2005302523A1 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury |
CN102036663A (zh) * | 2008-03-24 | 2011-04-27 | 细胞基因公司 | 用环丙基-n-{2-[(1s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲磺酰基)乙基]-3-氧代异吲哚啉-4基}甲酰胺治疗银屑病或者银屑病关节炎 |
WO2010093588A1 (en) | 2009-02-10 | 2010-08-19 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
RU2557236C2 (ru) * | 2009-10-09 | 2015-07-20 | Селджин Корпорейшн | Способ получения соединений 2-(1-фенилэтил)изоиндолин-1-она |
CA2794096A1 (en) | 2010-04-07 | 2011-10-13 | Celgene Corporation | Methods for treating respiratory viral infection |
CN103026229B (zh) | 2010-06-15 | 2016-03-30 | 细胞基因公司 | 用于治疗银屑病的生物标志物 |
EP2601950A1 (en) * | 2011-12-06 | 2013-06-12 | Sanofi | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists |
US20170087129A1 (en) | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
EP3157520B1 (en) | 2014-06-23 | 2019-09-04 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
TW332201B (en) * | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
-
1996
- 1996-12-03 US US08/759,788 patent/US5703098A/en not_active Expired - Lifetime
-
1997
- 1997-12-03 JP JP52584498A patent/JP2001506611A/ja not_active Ceased
- 1997-12-03 CA CA002273002A patent/CA2273002A1/en not_active Abandoned
- 1997-12-03 RU RU99113849/04A patent/RU2177471C2/ru not_active IP Right Cessation
- 1997-12-03 HU HU0000232A patent/HUP0000232A3/hu unknown
- 1997-12-03 AU AU55945/98A patent/AU735540B2/en not_active Ceased
- 1997-12-03 EP EP97952302A patent/EP0942902A2/en not_active Ceased
- 1997-12-03 SK SK732-99A patent/SK73299A3/sk unknown
- 1997-12-03 NZ NZ336713A patent/NZ336713A/en unknown
- 1997-12-03 WO PCT/US1997/022369 patent/WO1998024763A2/en not_active Application Discontinuation
- 1997-12-03 KR KR1019997005100A patent/KR20000069374A/ko not_active IP Right Cessation
- 1997-12-03 CN CNB971803234A patent/CN100372836C/zh not_active Expired - Fee Related
-
1999
- 1999-05-25 FI FI991187A patent/FI991187A/fi not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FI991187A0 (fi) | 1999-05-25 |
EP0942902A2 (en) | 1999-09-22 |
US5703098A (en) | 1997-12-30 |
WO1998024763A2 (en) | 1998-06-11 |
CN100372836C (zh) | 2008-03-05 |
KR20000069374A (ko) | 2000-11-25 |
HUP0000232A2 (hu) | 2000-09-28 |
RU2177471C2 (ru) | 2001-12-27 |
AU5594598A (en) | 1998-06-29 |
CN1254333A (zh) | 2000-05-24 |
CA2273002A1 (en) | 1998-06-11 |
SK73299A3 (en) | 1999-12-10 |
WO1998024763A3 (en) | 1998-08-06 |
NZ336713A (en) | 2001-02-23 |
HUP0000232A3 (en) | 2000-10-30 |
JP2001506611A (ja) | 2001-05-22 |
AU735540B2 (en) | 2001-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI991187A0 (fi) | Immunoterapeuttisia imidejä/amideja PDE IV ja TNF inhibiittoreina | |
NO983981D0 (no) | Isolert vegg og tilhörende komponenter | |
PL333918A1 (en) | Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors | |
DK0922697T3 (da) | Substituerede pyrazolylbenzensulfonamider og anvendelse deraf som cyclooxygenase II-inhibitorer | |
PL331254A1 (en) | Phosphonianic inhibitors of matrix metaloproteases | |
HUP9902034A3 (en) | Succinimide and maleimide cytokine inhibitors | |
EP0831800A4 (en) | ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THEIR USE AS FACTOR Xa INHIBITORS | |
IL128914A0 (en) | Heteroaryl succinamides and their use as metalloproteinase inhibitors | |
FI974437A (fi) | Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogeenifosforylaasi-inhibiittoreina | |
NO955034D0 (no) | Nye substituerte 1H-imidazoler og farmasöytiske preparater inneholdende disse | |
PL331047A1 (en) | Novel amidinic derivatives and their application as inhibitors of thrombosin | |
DK0934301T3 (da) | Aminothiophencarboxylsyreamider og anvendelse deraf som phosphodiesteraseinhibitorer | |
AP9700975A0 (en) | Substituted indazole derivatives and related compounds | |
PL331920A1 (en) | Spirocyclic inhibitors of metaloproteases | |
PL335378A1 (en) | Derivatives of inverse hydroxamates as metaloprotease inhibitors | |
DK0892796T3 (da) | Isatinderivater som acetylcholinesteraseinhibitorer og analgetika | |
NO980718D0 (no) | Bicykliske 4-aralkylaminopyrimidinderivater og tyrosinkinaseinhibitorer | |
AU5552698A (en) | Pharmaceutical compositions comprising diaryl-cyclomethylenpyrazole compounds and their use as cyclooxygenase i (cox i) inhibitors | |
NO983238D0 (no) | Exodus kjemokin materialer og fremgangsmater | |
DK0623614T3 (da) | 4-aryl-4-hydroxy-tetrahydropyraner og 3-aryl-3-hydroxy-tetrahydrofuraner som inhibitorer for 5-lipoxygenase | |
DK0983249T3 (da) | Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater | |
AU136833S (en) | Portable point of sale device | |
KR980003302U (ko) | 사무용 캐비닛의 손잡이 장치 | |
KR970056749U (ko) | 쇼케이스의 레일장치 | |
KR980005901U (ko) | 텔레비전의 브이씨알 받침대 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application lapsed |